Artificial intelligence (AI)🧠 in tumor boards offers advancements in oncology by improving diagnostics and personalized treatments🩻 However, its implementation faces challenges such as the lack of standardized protocols and anatomical variability, requiring human oversight to

🤲

🔍 Key findings from the IMbrave150 study in hepatocellular carcinoma: 1️⃣ 77.8% of patients with partial response (PR) and 28.5% with stable disease (SD) after treatment with atezolizumab + bevacizumab had durable responses. 2️⃣ Median progression-free survival was 23.2 months

🚨 This week's highlight in oncology research: Check out the new guide to navigating large cancer databases! 📊 SEER, the National Cancer Database, and others offer immense opportunities for cohort studies, but each has its strengths and limitations. Understanding these is

Dear Colleagues, The OncoAlert 🚨Network Presents OUR Picks of TOP 🔟Abstracts to be Presented at #ESMO24 This List Curated by: #OncoAlertAF Leads Elisa Agostinetto 🇮🇹 Elisabetta Bonzano MD, PhD 🇮🇹 Luca Arecco, MD 🇮🇹 Gil Morgan, MD 🇺🇸 With our distinguished OncoAlert Faculty: Sara Tolaney

📝 New EHA-ESMO Guidelines for HIV-Associated Lymphomas: The guidelines provide key recommendations for the diagnosis, treatment, and follow-up of lymphomas in patients with HIV: 🎯Initiation/optimization of cART (combined antiretroviral therapy). 🎯Rituximab as first-line

Dear Colleagues, The OncoAlert 🚨Network Presents OUR Picks of TOP 🔟 #LungCancer 🫁Abstracts to be Presented at #ESMO24 This List Curated by: #OncoAlertAF Leads Hidehito HORINOUCHI 🇯🇵 Biagio Ricciuti, MD PhD 🇺🇸 Eric K. Singhi, MD 🇺🇸 Gil Morgan, MD 🇺🇸 With our Distinguished OncoAlert 🚨Faculty

🚨 Advances in the treatment of advanced ALK+ lung cancer🫁 (CROWNtrial): 🔴Lorlatinib, a third-generation TKI, demonstrates a median progression-free survival of over 5 years in advanced ALK+ NSCLC, according to the #CROWNtrial. 🟠With several second- and third-generation TKIs

🚨 The OncoAlert Newsletter is NOW OUT! 🚨 Covering August 30 - September 5, 2024: Register here 👉 Oncoalert360.com 🗨️ Comment: One of the studies that interested me the most was Cohort 2 TROPHY-U-01, a phase II study on sacituzumab govitecan in patients with

Dear Colleagues, The OncoAlert 🚨Network Presents OUR Picks of TOP 🔟+1⃣ Abstracts on #BladderCancer and #KidneyCancer to be Presented at #ESMO24 This List Curated by: #OncoAlertAF Leads Dra. María Natalia Gandur Quiroga 🇦🇷 Emre Yekedüz 🇺🇸 Gil Morgan, MD 🇺🇸 and our distinguished faculty

Dear Colleagues, The OncoAlert 🚨Network Presents OUR Picks of TOP 🔟+1⃣ Abstracts on #ProstateCancer to be Presented at #ESMO24 This List Curated by: #OncoAlertAF Leads Dra. María Natalia Gandur Quiroga 🇦🇷 Emre Yekedüz 🇺🇸 Bárbara Melão, MD 🇧🇷 Gil Morgan, MD 🇺🇸 and our distinguished faculty

🚨 Final results of the PANTHER trial in high-risk early-stage #BreastCancer: 🧪Dose-dense adjuvant chemotherapy (tDD) vs. standard: 📉Breast Cancer Recurrence-Free Survival (RFS): Significant improvement (HR 0.80; 95% CI: 0.65-0.98; P=0.030). 📉Event-Free Survival (EFS):

🚨Abemaciclib, a CDK4/6 inhibitor approved by the FDA for HR+/HER2− breast cancer, shows therapeutic potential in endometrial cancer🙀. A phase II trial reports efficacy and good tolerance when combined with aromatase inhibitors in endometrioid #endometrialcancer. 🔷These

🚨 The FDA approved atezolizumab and hyaluronidase-tqjs for subcutaneous injection in adults for all indications of its intravenous formulation, including NSCLC, SCLC, HCC, melanoma, and ASPS. 📉In the IMscin001 trial, the confirmed

🙌🙌

✨Amazing presentation by Loic Ysebaert at #ESMO2024! Real-world data from the DESCAR-T registry show an ORR of 98.2% and CRR of 85.8% for Tisa-cel in relapsed/refractory follicular lymphoma. 🚀 Safety profile remains strong, with low rates of severe CRS and neurotoxicity. Big

👏 Big thanks to Elizabeth A. Connolly from Sydney, Australia, for presenting "Can proteomics predict metastatic relapse in leiomyosarcoma (LMS)? Development of an 8 protein signature in a >350 sample study including a validation cohort" at #ESMO2024! This groundbreaking study

Thank you, Josep Tabernero, for your brilliant talk on EC + FOLFIRI in BRAF V600E-mutant mCRC at #ESMO2024! 🧬 The updated results from the BREAKWATER study are encouraging, showing promising antitumor activity with good tolerability. Certainly, a great step forward in mCRC

Thank you, Dr. Sun Young Rha, for your enlightening talk🌟🌟🌟 on Zanidatamab + chemotherapy in 1L HER2+ mCRC at #ESMO2024! 🧬 The study shows promising antitumor activity with a confirmed objective response rate of 91% and a manageable safety profile. Exciting data for the

Thank you, M.D Kaysia Ludford, for your excellent presentation on long-term survival and organ preservation with pembrolizumab in localized MSI-H/dMMR tumors at #ESMO2024! 🧬 The study shows impressive 3-year DFS (80%) and OS (94%) rates✨✨, with promising organ preservation